Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Running

PANNEXIN Pannexin 1 – a novel target for pediatric orphan epilepsy

Coordinator
Panntherapi, France
Runs
1 October 2023 to 31 March 2026
Status
Running
EU funding
€2.5m
Total cost
€4.1m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190121670

What the project is doing

In the project's own words, from its summary on CORDIS.

Epilepsy is a group of syndromes with high unmet medical need, especially in children as frequent seizures affect the immature brain and its development. In some orphan syndromes, drug resistance is 70% with dramatic consequences for patients and their families. Novel treatments must prevent the negative effects of seizures, but also minimize off-target effects on brain development and cognitive functions. Our solution is the specific blockade of the activated form of the Pannexin 1 (Panx1) channel using a reformulated form of probenecid: PTI5803.

This compound, a first-in-class drug, inhibits seizures preclinically in >80% of cases without hampering cognitive functions. Designed to be adapted to children (from 6 months of age) and to improve the bioavailability, PTI5803 is a highly specific breakthrough product to counteract the pathological activation of Panx1 in patients with an ultra-resistant orphan epilepsy, with the potential to disrupt the market of paediatric epilepsy.

Topics

Who is involved

OrganisationCityCountryRole
PanntherapiNimesFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI